{"acute kidney injury": 2.13, "autoimmune colitis": 152.33, "autoimmune hepatitis": 18.65, "colitis": 20.53, "diabetes mellitus": 2.38, "febrile neutropenia": 2.56, "general physical health deterioration": 4.36, "hepatitis": 16.45, "hyperthyroidism": 28.37, "hyponatraemia": 3.71, "hypophysitis": 42.03, "hypothyroidism": 14.82, "hypoxia": 5.64, "immune-mediated enterocolitis": 11.53, "immune-mediated lung disease": 18.0, "intentional product use issue": 18.36, "interstitial lung disease": 6.03, "liver disorder": 3.06, "malignant neoplasm progression": 15.2, "metastases to central nervous system": 9.7, "myocarditis": 2.08, "myositis": 11.73, "neoplasm progression": 2.45, "neuropathy peripheral": 2.71, "neutrophil count decreased": 2.79, "off label use": 2.51, "pemphigoid": 8.41, "pleural effusion": 3.13, "pneumonitis": 15.21, "product use in unapproved indication": 3.31, "rash maculo-papular": 4.77, "respiratory failure": 2.2, "sepsis": 2.31, "thyroiditis": 15.66, "transaminases increased": 2.98, "tubulointerstitial nephritis": 16.05, "tumour pseudoprogression": 54.27, "white blood cell count decreased": 2.16}